Across TCGA pan-cancer cohorts, PNMA3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PNMA3 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PNMA3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PNMA3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC and LSCC are the cancer types where PNMA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.128	0.794	.038	3	view →
LSCC	DFS	Tertile	All	1.000	0.535	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PNMA3 tumor-vs-normal RNA expression · all PNMA3 data types